$ELAB
PMGC Holdings Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024097678 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $527.5K
YoY Change -99.9%
Cost Of Revenue $133.6K
YoY Change -99.93%
Gross Profit $393.9K
YoY Change -99.89%
Gross Profit Margin 74.68%
Selling, General & Admin $1.215M
YoY Change -99.84%
% of Gross Profit 308.43%
Research & Development $95.26K
YoY Change -99.89%
% of Gross Profit 24.18%
Depreciation & Amortization -$36.24K
YoY Change 2776.19%
% of Gross Profit -9.2%
Operating Expenses $1.314M
YoY Change -99.89%
Operating Profit -$919.8K
YoY Change -99.88%
Interest Expense -$583.6K
YoY Change -110.22%
% of Operating Profit
Other Income/Expense, Net $1.340K
YoY Change -100.0%
Pretax Income -$1.501M
YoY Change 91.72%
Income Tax
% Of Pretax Income
Net Earnings -$1.501M
YoY Change -99.81%
Net Earnings / Revenue -284.61%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.07
COMMON SHARES
Basic Shares Outstanding 517.7M shares 20.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.426M
YoY Change 1247.5%
Cash & Equivalents $6.426M
Short-Term Investments
Other Short-Term Assets $787.9K
YoY Change 169.76%
Inventory $986.4K
Prepaid Expenses
Receivables $16.89K
Other Receivables $11.00K
Total Short-Term Assets $8.228M
YoY Change -99.36%
LONG-TERM ASSETS
Property, Plant & Equipment $52.53K
YoY Change -99.91%
Goodwill
YoY Change
Intangibles $2.824M
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $2.978M
YoY Change -99.03%
TOTAL ASSETS
Total Short-Term Assets $8.228M
Total Long-Term Assets $2.978M
Total Assets $11.21M
YoY Change -99.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.079M
YoY Change 88.23%
Accrued Expenses $137.6K
YoY Change -49.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.130M
YoY Change -99.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $519.7K
YoY Change 403.06%
Total Long-Term Liabilities $519.7K
YoY Change 403.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.130M
Total Long-Term Liabilities $519.7K
Total Liabilities $2.650M
YoY Change -99.85%
SHAREHOLDERS EQUITY
Retained Earnings -$11.33M
YoY Change -99.81%
Common Stock $19.89M
YoY Change 1865.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.555M
YoY Change
Total Liabilities & Shareholders Equity $11.21M
YoY Change -99.29%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.501M
YoY Change -99.81%
Depreciation, Depletion And Amortization -$36.24K
YoY Change 2776.19%
Cash From Operating Activities -$381.7K
YoY Change -26.41%
INVESTING ACTIVITIES
Capital Expenditures $50.00K
YoY Change 4101.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$50.00K
YoY Change 4101.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.758M
YoY Change 1627.86%
NET CHANGE
Cash From Operating Activities -381.7K
Cash From Investing Activities -50.00K
Cash From Financing Activities 6.758M
Net Change In Cash 6.326M
YoY Change -5012.88%
FREE CASH FLOW
Cash From Operating Activities -$381.7K
Capital Expenditures $50.00K
Free Cash Flow -$431.7K
YoY Change -16.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41875
dei Entity Registrant Name
EntityRegistrantName
ELEVAI LABS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1399981
dei Entity Address Address Line1
EntityAddressAddressLine1
Graydon Bensler
dei Entity Address Address Line2
EntityAddressAddressLine2
120 Newport Center Drive
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Newport Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92660
dei City Area Code
CityAreaCode
(866)
dei Local Phone Number
LocalPhoneNumber
794-4940
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ELAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
517661269 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6425670 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3326851 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
27887 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
36161 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
787848 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1060765 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
986421 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
495667 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
8227826 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4919444 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10773 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52528 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53119 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2823530 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101471 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
206582 usd
CY2024Q3 us-gaap Assets
Assets
11205355 usd
CY2023Q4 us-gaap Assets
Assets
5189918 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1216191 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
669375 usd
CY2024Q3 us-gaap Customer Deposits Current
CustomerDepositsCurrent
39583 usd
CY2023Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
36693 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
350000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103309 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
145000 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1882 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
369158 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2130422 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1297353 usd
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
519711 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
65489 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2650133 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1362842 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49376039 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49376039 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17329615 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17329615 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4938 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1733 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19884944 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10849031 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
228 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
202 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11334888 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7023890 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8555222 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3827076 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11205355 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5189918 usd
CY2024Q3 us-gaap Revenues
Revenues
527478 usd
CY2023Q3 us-gaap Revenues
Revenues
554654 usd
us-gaap Revenues
Revenues
1747570 usd
us-gaap Revenues
Revenues
1014004 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
133577 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
188509 usd
us-gaap Cost Of Revenue
CostOfRevenue
468763 usd
us-gaap Cost Of Revenue
CostOfRevenue
341122 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
393901 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
366145 usd
us-gaap Gross Profit
GrossProfit
1278807 usd
us-gaap Gross Profit
GrossProfit
672882 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2686 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2439 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7779 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7824 usd
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
94514 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
99709 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1209041 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
316436 usd
CY2024Q3 us-gaap Management Fee Expense
ManagementFeeExpense
235461 usd
CY2023Q3 us-gaap Management Fee Expense
ManagementFeeExpense
82781 usd
us-gaap Management Fee Expense
ManagementFeeExpense
817030 usd
us-gaap Management Fee Expense
ManagementFeeExpense
316468 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
553808 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
664922 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2096372 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1628931 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
249889 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
143654 usd
us-gaap Professional Fees
ProfessionalFees
587954 usd
us-gaap Professional Fees
ProfessionalFees
450384 usd
CY2024Q3 elab Investor Relations
InvestorRelations
36862 usd
CY2023Q3 elab Investor Relations
InvestorRelations
9100 usd
elab Investor Relations
InvestorRelations
141484 usd
elab Investor Relations
InvestorRelations
84820 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95260 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86374 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
268786 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
303769 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-875 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3113 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1660 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
480 usd
CY2024Q3 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
44383 usd
CY2023Q3 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
65830 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
160612 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
250000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1313738 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1151696 usd
us-gaap Operating Expenses
OperatingExpenses
5290718 usd
us-gaap Operating Expenses
OperatingExpenses
3358152 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-919837 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-785551 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4011911 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2685270 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-65474 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8192 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-367277 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
451054 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
648332 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5713 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
702675 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12758 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
95 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
25 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
245 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5481 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1343 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
36066 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1501257 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-783047 usd
us-gaap Net Income Loss
NetIncomeLoss
-4310998 usd
us-gaap Net Income Loss
NetIncomeLoss
-3143601 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1014 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
387 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
26 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
762 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1502271 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-782660 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4310972 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3142839 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.068
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.068
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.078
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.078
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.226
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.226
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.318
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.318
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22159118 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10023002 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19105176 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9900744 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
67288 usd
CY2023Q3 elab Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
389997 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
161480 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-783047 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
387 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-163895 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2639636 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7045000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
325819 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
47038 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1501257 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1014 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8555222 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1131310 usd
elab Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
1463586 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37500 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
346548 usd
us-gaap Net Income Loss
NetIncomeLoss
-3143601 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
762 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-163895 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3827076 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1610778 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7045000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
325819 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
57521 usd
us-gaap Net Income Loss
NetIncomeLoss
-4310998 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
26 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8555222 usd
us-gaap Net Income Loss
NetIncomeLoss
-4310998 usd
us-gaap Net Income Loss
NetIncomeLoss
-3143601 usd
us-gaap Depreciation
Depreciation
9715 usd
us-gaap Depreciation
Depreciation
8737 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57521 usd
us-gaap Share Based Compensation
ShareBasedCompensation
346548 usd
us-gaap Straight Line Rent
StraightLineRent
2069 usd
us-gaap Straight Line Rent
StraightLineRent
2068 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-367277 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
451054 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
671578 usd
elab Research And Development Costs For Intangible Assets
ResearchAndDevelopmentCostsForIntangibleAssets
61019 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-8266 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4507 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-283722 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
138636 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
490754 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
269164 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
383119 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
449281 usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
2890 usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
44681 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
206833 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
80000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3486435 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2168661 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9160 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11191 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
162320 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171480 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11191 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6993059 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1463586 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
914442 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1150000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
37500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6757501 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1501086 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-767 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
720 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3098819 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-678046 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3326851 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1154901 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6425670 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
476855 usd
us-gaap Interest Paid Net
InterestPaidNet
23248 usd
us-gaap Interest Paid Net
InterestPaidNet
4898 usd
elab Common Stock Issued And Issuable On Acquisition Of Intangible Asset
CommonStockIssuedAndIssuableOnAcquisitionOfIntangibleAsset
1610778 usd
us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.5in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b>Organization and nature of operations</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiaries, Elevai Research Inc., Elevai Skincare Inc., and Elevai Biosciences, Inc., are collectively referred to in these unaudited condensed consolidated financial statements as “the Company.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 29, 2024, Elevai Skincare Inc. ("Skincare”) and Elevai Biosciences, Inc. (“BioSciences”) were incorporated under the laws of the state of Delaware. Elevai is the sole shareholder of Skincare and BioSciences. The purpose of Skincare is to operate the Company’s existing business, while the purpose of BioSciences is to hold and develop the Company’s intellectual property. Effective May 1, 2024, Elevai transferred its operating assets and liabilities relating to its skincare business to Skincare in exchange for common stock of Skincare.</p>
CY2024Q3 elab Net Working Capital
NetWorkingCapital
6097404 usd
CY2023Q4 elab Net Working Capital
NetWorkingCapital
3622091 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11334888 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7023890 usd
us-gaap Net Income Loss
NetIncomeLoss
-4310998 usd
us-gaap Net Income Loss
NetIncomeLoss
-3143601 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3486435 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2168661 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined.</p>
CY2024Q3 elab Trade Receivable
TradeReceivable
16889 usd
CY2023Q4 elab Trade Receivable
TradeReceivable
33089 usd
CY2024Q3 elab Sales Taxes Receivable
SalesTaxesReceivable
10998 usd
CY2023Q4 elab Sales Taxes Receivable
SalesTaxesReceivable
3072 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
27887 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
36161 usd
CY2024Q3 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
651984 usd
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
957645 usd
CY2024Q3 us-gaap Deposit Assets
DepositAssets
135864 usd
CY2023Q4 us-gaap Deposit Assets
DepositAssets
113893 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
787848 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1071538 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
787848 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1060765 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10773 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10773 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
439328 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
279514 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
289113 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
147906 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
257980 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
68247 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
986421 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
495667 usd
us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
214272 usd
us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
193805 usd
us-gaap Marketing Expense
MarketingExpense
134000 usd
us-gaap Marketing Expense
MarketingExpense
96184 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61640 usd
CY2023 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
11191 usd
CY2023 elab Property Plant And Equipment Foreign Currency Translation
PropertyPlantAndEquipmentForeignCurrencyTranslation
61 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
72892 usd
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
9160 usd
elab Property Plant And Equipment Foreign Currency Translation
PropertyPlantAndEquipmentForeignCurrencyTranslation
-54 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
81998 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8105 usd
CY2023 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
11649 usd
CY2023 elab Equipment Foreign Currency Translation Accumulated Depreciation
EquipmentForeignCurrencyTranslationAccumulatedDepreciation
19 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19773 usd
us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
9715 usd
elab Equipment Foreign Currency Translation Accumulated Depreciation
EquipmentForeignCurrencyTranslationAccumulatedDepreciation
-18 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29470 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53119 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52528 usd
CY2024Q3 us-gaap Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities
CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities
1936 usd
CY2023Q3 us-gaap Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities
CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities
914 usd
CY2024Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2024Q1 elab Purchase Price
PurchasePrice
1000000 usd
CY2024Q1 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
600000 usd
CY2024Q3 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
400000 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
950000 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
492850 usd
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
173100 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2450000 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
612500 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
612500 shares
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
612500 shares
elab Finite Lived Intangible Assets Additions
FiniteLivedIntangibleAssetsAdditions
2884549 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2884549 usd
elab Finite Lived Intangible Assets Accumulated Amortization Additions
FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions
61019 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
61019 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2823530 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
47986 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.115 pure
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08 pure
us-gaap Operating Lease Cost
OperatingLeaseCost
119222 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
103000 usd
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
90863 usd
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
74640 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
18688 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
23705 usd
elab Lab Space Capitalized To Production Of Inventory
LabSpaceCapitalizedToProductionOfInventory
9671 usd
elab Lab Space Capitalized To Production Of Inventory
LabSpaceCapitalizedToProductionOfInventory
4655 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
119222 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
103000 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
10773 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
10773 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
40430 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
67384 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
107814 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4505 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
103309 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103309 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M1D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M1D
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1078624 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
596147 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137567 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73228 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1216191 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
669375 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
950000 usd
elab Consideration Payable Discount
ConsiderationPayableDiscount
138548 usd
elab Consideration Payable Additions
ConsiderationPayableAdditions
861452 usd
elab Consideration Payable Payment
ConsiderationPayablePayment
-50000 usd
elab Consideration Accretion Expense
ConsiderationAccretionExpense
58259 usd
CY2024Q3 us-gaap Loans Payable
LoansPayable
869711 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
350000 usd
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
519711 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
231828 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.01
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
231828 shares
CY2023Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2027-04-27
us-gaap Notes Issued1
NotesIssued1
622239 usd
elab Transaction Costs
TransactionCosts
-85558 usd
us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
613319 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1150000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49376039 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49376039 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17329615 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17329615 shares
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
492850 usd
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1117710 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1299999 shares
CY2024Q3 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
51942 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
130 usd
CY2024Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
325689 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
8900000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
19671425 shares
CY2024Q3 us-gaap Defined Benefit Plan Funded Percentage
DefinedBenefitPlanFundedPercentage
0.0499 pure
CY2024Q3 elab Issuance Warrants Percentage
IssuanceWarrantsPercentage
0.0999 pure
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.28
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
955000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2857 usd
CY2024Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
7042143 usd
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
62500 shares
CY2023Q1 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
0.6
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
37500 usd
CY2023Q1 elab Purchase Of Common Stock Warrants
PurchaseOfCommonStockWarrants
250000 shares
CY2023Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
293579 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5 usd
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
139995 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8 usd
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
249996 usd
elab Floor Price
FloorPrice
0.056
CY2024Q3 elab Expiration Term
ExpirationTerm
P180D
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y9M21D
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y9M21D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2024Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
5
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
16178 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2024Q1 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
1
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
52845 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2023Q1 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
5
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
10767 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2023Q2 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
5
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
584787 usd
CY2023Q2 elab Percentage Of Option Vesting For Remaining Period
PercentageOfOptionVestingForRemainingPeriod
0.75 pure
CY2023Q2 us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
80000 shares
CY2023Q2 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
5
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2023Q3 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
5
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3940 usd
CY2023Q3 elab Options Vest Percentage
OptionsVestPercentage
0.25 pure
CY2023Q3 elab Remaining Options Vest Percentage
RemainingOptionsVestPercentage
0.75 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1366167 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
234000 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14583 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.6
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
62500 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.6
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1523084 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
92500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
394990 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.2
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1220594 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.52
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10D
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2024Q3 elab Percentage Of Authority Control
PercentageOfAuthorityControl
0.10 pure
CY2024Q1 elab Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Right Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightPercentage
0.25 pure
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
-1819 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
145516 usd
elab Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
1049898 usd
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
354990 shares
CY2024Q3 us-gaap Interest Bearing Deposit Liabilities
InterestBearingDepositLiabilities
22217 usd
CY2023Q4 us-gaap Interest Bearing Deposit Liabilities
InterestBearingDepositLiabilities
22455 usd
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
200000 usd
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.20 pure
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
6833 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
139149 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Noncash Expense
OtherNoncashExpense
usd
elab Research And Development Costs For Intangible Assets
ResearchAndDevelopmentCostsForIntangibleAssets
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
elab Common Stock Issued And Issuable On Acquisition Of Intangible Asset
CommonStockIssuedAndIssuableOnAcquisitionOfIntangibleAsset
usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
usd
CY2024Q3 us-gaap Inventory Net Of Allowances Customer Advances And Progress Billings
InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings
usd
CY2023Q4 us-gaap Inventory Net Of Allowances Customer Advances And Progress Billings
InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings
usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q4 us-gaap Loans Payable
LoansPayable
usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
usd
CY2024Q3 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001840563

Files In Submission

Name View Source Status
0001213900-24-097678-index-headers.html Edgar Link pending
0001213900-24-097678-index.html Edgar Link pending
0001213900-24-097678.txt Edgar Link pending
0001213900-24-097678-xbrl.zip Edgar Link pending
ea0219720-10q_elevai.htm Edgar Link pending
ea021972001ex31-1_elevai.htm Edgar Link pending
ea021972001ex31-2_elevai.htm Edgar Link pending
ea021972001ex32-1_elevai.htm Edgar Link pending
ea021972001ex32-2_elevai.htm Edgar Link pending
elab-20240930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
elab-20240930_cal.xml Edgar Link unprocessable
elab-20240930_def.xml Edgar Link unprocessable
elab-20240930_lab.xml Edgar Link unprocessable
elab-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0219720-10q_elevai_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending